octanoic acid has been researched along with Sensitivity and Specificity in 24 studies
octanoic acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #1764
octanoic acid : A straight-chain saturated fatty acid that is heptane in which one of the hydrogens of a terminal methyl group has been replaced by a carboxy group. Octanoic acid is also known as caprylic acid.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (12.50) | 18.2507 |
2000's | 15 (62.50) | 29.6817 |
2010's | 6 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Nguyen, NQ | 1 |
Bryant, LK | 1 |
Burgstad, CM | 1 |
Chapman, M | 1 |
Deane, A | 1 |
Bellon, M | 2 |
Lange, K | 1 |
Bartholomeuz, D | 1 |
Horowitz, M | 1 |
Holloway, RH | 1 |
Fraser, RJ | 1 |
De Preter, V | 1 |
Machiels, K | 1 |
Joossens, M | 1 |
Arijs, I | 1 |
Matthys, C | 1 |
Vermeire, S | 1 |
Rutgeerts, P | 1 |
Verbeke, K | 2 |
Pendela, M | 1 |
Dragovic, S | 1 |
Bockx, L | 1 |
Hoogmartens, J | 1 |
Van Schepdael, A | 1 |
Adams, E | 1 |
Bergeron, SJ | 1 |
Henry, ID | 1 |
Santini, RE | 1 |
Aghdasi, A | 1 |
Raftery, D | 1 |
Herrera, M | 1 |
Meneses, F | 1 |
Gutiérrez, JM | 1 |
León, G | 1 |
de Loor, H | 1 |
Meijers, BK | 1 |
Meyer, TW | 1 |
Bammens, B | 1 |
Dehaen, W | 1 |
Evenepoel, P | 1 |
Yamamoto, K | 1 |
Hakamata, H | 1 |
Yamaguchi, A | 1 |
Kusu, F | 1 |
Keller, J | 1 |
Brückel, S | 1 |
Jahr, C | 1 |
Layer, P | 1 |
Cardeñosa, V | 1 |
Lunar, ML | 1 |
Rubio, S | 1 |
Unger, MM | 1 |
Möller, JC | 1 |
Mankel, K | 1 |
Schmittinger, K | 1 |
Eggert, KM | 1 |
Stamelou, M | 1 |
Stiasny-Kolster, K | 1 |
Bohne, K | 1 |
Bodden, M | 1 |
Mayer, G | 1 |
Oertel, WH | 1 |
Tebbe, JJ | 1 |
Gutierrez, JA | 1 |
Willency, JA | 1 |
Knierman, MD | 1 |
Coskun, T | 1 |
Solenberg, PJ | 1 |
Perkins, DR | 1 |
Higgs, RE | 1 |
Hale, JE | 1 |
Bromer, MQ | 1 |
Kantor, SB | 1 |
Wagner, DA | 1 |
Knight, LC | 1 |
Maurer, AH | 1 |
Parkman, HP | 1 |
Sutton, DG | 1 |
Bahr, A | 1 |
Preston, T | 1 |
Christley, RM | 1 |
Love, S | 1 |
Roussel, AJ | 1 |
van de Casteele, M | 1 |
Luypaerts, A | 1 |
Geypens, B | 1 |
Fevery, J | 1 |
Ghoos, Y | 1 |
Nevens, F | 1 |
Miele, L | 1 |
Grieco, A | 1 |
Armuzzi, A | 1 |
Candelli, M | 1 |
Forgione, A | 1 |
Gasbarrini, A | 1 |
Gasbarrini, G | 1 |
Chew, CG | 1 |
Bartholomeusz, FD | 1 |
Chatterton, BE | 1 |
Minderhoud, IM | 1 |
Mundt, MW | 1 |
Roelofs, JM | 1 |
Samsom, M | 1 |
Jackson, SJ | 1 |
Bluck, LJ | 1 |
Kasicka-Jonderko, A | 1 |
Kamińska, M | 1 |
Jonderko, K | 1 |
Setera, O | 1 |
Błońska-Fajfrowska, B | 1 |
Redwan, el-RM | 1 |
Bennett, MJ | 1 |
Ragni, MC | 1 |
Ostfeld, RJ | 1 |
Santer, R | 1 |
Schmidt-Sommerfeld, E | 1 |
Vandenvelde, C | 1 |
Scheen, R | 1 |
Defoor, M | 1 |
Duys, M | 1 |
Dumon, J | 1 |
Van Beers, D | 1 |
Perri, F | 2 |
Clemente, R | 1 |
Festa, V | 1 |
Quitadamo, M | 1 |
Niro, G | 1 |
Andriulli, A | 2 |
Delbende, B | 1 |
Couturier, O | 1 |
Leodolter, A | 1 |
Mauger, P | 1 |
Bridgi, B | 1 |
Bizais, Y | 1 |
des Varannes, SB | 1 |
Galmiche, JP | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Characterization of Disease Related Changes in Inflammatory Bowel Disease Using Fecal Metabolite Profiling[NCT01666717] | 204 participants (Actual) | Observational | 2008-08-31 | Completed | |||
Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis[NCT01323582] | Phase 2 | 26 participants (Actual) | Interventional | 2009-02-28 | Terminated (stopped due to Original investigator left this institution, replacement investigator retired.) | ||
Cardiovascular Function and Postprandial Hypotension (PPH): Effect of an Oral Glucose Load on Cardiac Contractility, Cardiac Output, Diastolic Function and Endothelial Function - Relationship to Gastric Emptying[NCT02713412] | 8 participants (Actual) | Interventional | 2013-04-30 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Patients will be given a standardized meal enriched with a labeled material and the breath samples are then collected and analyzed. The estimated time to reaching 50% of the accumulated contents is recorded. (NCT01323582)
Timeframe: at baseline before initiation of the treatment and after completion of each treatment period.
Intervention | minutes (Mean) |
---|---|
Azithromycin | -15.0 |
Patients will be given a standardized meal enriched with a labeled material and the breath samples are then collected and analyzed. The estimated time to reaching 50% of the accumulated contents is recorded. (NCT01323582)
Timeframe: Baseline and end of treatment period
Intervention | Minutes (Mean) |
---|---|
Erythromycin | -11.8 |
"This is a Validated instrument for measuring symptom severity in patients with gastroparesis. This scoring is based on a Likert Scale from (0-5) with zero being no symptom and five being very severe symptoms on 9 subscales, making the overall score range from 0-45. The higher the score, the more severe patient's symptoms are. The scale is reported in the references.~This is a calculation taken with GCSI score at end of treatment minus baseline. Negative value reflects this change." (NCT01323582)
Timeframe: Baseline and end of treatment period
Intervention | units on a scale (Median) |
---|---|
Azithromycin | -6.40 |
"This is a Validated instrument for measuring symptom severity in patients with gastroparesis. This scoring is based on a Likert Scale from (0-5) with zero being no symptoms and five being very severe symptoms on 9 subscales, making the overall score range from 0-45. The higher the score, the more severe patient's symptoms.~Reference for GCSI: Revicki DA, REntz AM, Dubois D, et al. Development and validation of a patient-assessed gastroparesis symptoms severity measure: the Gastroparesis Cardinal Symptom Index. Ailment Pharm Ther 2003; 18: 141:50.~Because the difference is RX-B -RX A in one group and RX A -RX B in the other, the difference between these two estimates twice the effect size. Hence the Half is applied, as is standard in the two sample method for crossover studies." (NCT01323582)
Timeframe: Weeks 4 and 11 (end of periods)
Intervention | units on a scale (Mean) |
---|---|
Erythromycin First Then Azithromycin | -1.6 |
Azithromycin Then Erythromycin | -2.9 |
"This is a Validated instrument for measuring symptom severity in patients with gastroparesis. This scoring is based on a Likert Scale from (0-5) with zero being no symptom and five being very severe symptoms on 9 subscales, making the overall score range from 0-45. The higher the score, the more severe patient's symptoms are. The scale is reported in the references. The change was calculated by measuring the end of treatment minus baseline GCSI score.~Negative value reflects this change." (NCT01323582)
Timeframe: Baseline and end of treatment period
Intervention | units on a scale (Mean) |
---|---|
Erythromycin | -5.32 |
"Nepean Dyspepsia Index (NDI) is a measure of symptom status and quality of life in functional dyspepsia. This scale is scored using each subscale (Tension, interference with daily activities), Eating/drinking, Knowledge/control, work/study) and adding up the items for each of the five subscale score (2-10). Total score range would be 10-50).~For the NDI, a lower number is better meaning the symptom is not effecting quality of life and a higher score closer to 50 is worse meaning it is effecting patients quality of life.~Reference: Talley NJ, Verlinden M, Jones M. Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and developement of a new 10-iten short form. Aliment Pharmacol Ther 2001: 15: 207-216.~Because the difference is RX-B -RX A in one group and RX A -RX B in the other, the difference between these two estimates twice the effect size. Hence the Half is applied, as is standard in the two sample method for crossover studies." (NCT01323582)
Timeframe: Weeks 4 and 11 (end of periods)
Intervention | units on a scale (Median) |
---|---|
Erythromycin First Then Azithromycin | 1.65 |
Azithromycin Then Erythromycin | 1.30 |
Patients will be given a standardized meal enriched with a labeled material and the breath samples are then collected and analyzed. The estimated time to empty 50% (t 1/2) of the accumulated contents is recorded. Because the difference is RX-B -RX A in one group and RX A -RX B in the other, the difference between these two estimates twice the effect size. Hence the Half is applied, as is standard in the two sample method for crossover studies. (NCT01323582)
Timeframe: Weeks 4 and 11 (end of periods)
Intervention | Minutes (Mean) |
---|---|
Erythromycin First Then Azithromycin | -1.6 |
Azithromycin Then Erythromycin | -5.2 |
This is defined as the time from ingestion of the meal to the beginning of the emptying process in minutes. Because the difference is RX-B -RX A in one group and RX A -RX B in the other, the difference between these two estimates twice the effect size. Hence the Half is applied, as is standard in the two sample method for crossover studies. (NCT01323582)
Timeframe: Weeks 4 and 11 (end of periods)
Intervention | Minutes (Mean) |
---|---|
Erythromycin First Then Azithromycin | -1.71 |
Azithromycin Then Erythromycin | -0.22 |
2 reviews available for octanoic acid and Sensitivity and Specificity
Article | Year |
---|---|
Measurement of gastric emptying by octanoate metabolism.
Topics: Breath Tests; Caprylates; Gastric Emptying; Humans; Radionuclide Imaging; Reproducibility of Results | 2005 |
13C-octanoic acid breath test: a reliable tool for measuring gastric emptying.
Topics: Breath Tests; Caprylates; Carbon Dioxide; Carbon Isotopes; Female; Gastric Emptying; Gastritis; Huma | 1998 |
3 trials available for octanoic acid and Sensitivity and Specificity
Article | Year |
---|---|
Patients with idiopathic rapid-eye-movement sleep behavior disorder show normal gastric motility assessed by the 13C-octanoate breath test.
Topics: Adult; Aged; Breath Tests; Caprylates; Carbon Isotopes; Enteric Nervous System; Female; Gastric Empt | 2011 |
Simultaneous 13C/14C dual isotope breath test measurement of gastric emptying of solid and liquid in normal subjects and patients: comparison with scintigraphy.
Topics: Acetates; Administration, Oral; Adult; Age Factors; Aged; Breath Tests; Caprylates; Carbon Radioisot | 2003 |
Gastric emptying of a solid meal starts during meal ingestion: combined study using 13C-octanoic acid breath test and Doppler ultrasonography. Absence of a lag phase in 13C-octanoic acid breath test.
Topics: Adult; Breath Tests; Caprylates; Carbon Isotopes; Eggs; Feeding Behavior; Female; Gastric Emptying; | 2004 |
19 other studies available for octanoic acid and Sensitivity and Specificity
Article | Year |
---|---|
Gastric emptying measurement of liquid nutrients using the (13)C-octanoate breath test in critically ill patients: a comparison with scintigraphy.
Topics: Breath Tests; Caprylates; Carbon Isotopes; Critical Illness; Enteral Nutrition; Female; Gastric Empt | 2013 |
Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD.
Topics: Adolescent; Adult; Aged; Caproates; Caprylates; Case-Control Studies; Colitis, Ulcerative; Crohn Dis | 2015 |
Development of a liquid chromatographic method for the determination of related substances and assay of d-cycloserine.
Topics: Acetonitriles; Antibiotics, Antitubercular; Biological Assay; Buffers; Caprylates; Capsules; Chromat | 2008 |
Saturation transfer double-difference NMR spectroscopy using a dual solenoid microcoil difference probe.
Topics: Caprylates; Glucose; Humans; Ligands; Magnetic Resonance Spectroscopy; Polyurethanes; Reference Stan | 2008 |
Development and validation of a reverse phase HPLC method for the determination of caprylic acid in formulations of therapeutic immunoglobulins and its application to antivenom production.
Topics: Animals; Antivenins; Caprylates; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Ho | 2009 |
Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography.
Topics: Albumins; Caprylates; Chromatography, Liquid; Cresols; Fluorescence; Humans; Indican; Kidney Disease | 2009 |
An LC method for monitoring medium-chain fatty acid permeation through CaCo-2 cell monolayers.
Topics: Benzoquinones; Caco-2 Cells; Caprylates; Cell Membrane Permeability; Chromatography, High Pressure L | 2009 |
A modified ¹³C-mixed triglyceride breath test detects moderate pancreatic exocrine insufficiency.
Topics: Adult; Aged; Breath Tests; Caprylates; Carbon Isotopes; Exocrine Pancreatic Insufficiency; Female; G | 2011 |
Generalized and rapid supramolecular solvent-based sample treatment for the determination of annatto in food.
Topics: Bixaceae; Caprylates; Carotenoids; Chromatography, Liquid; Food Analysis; Food Coloring Agents; Fura | 2011 |
From ghrelin to ghrelin's O-acyl transferase.
Topics: Acylation; Acyltransferases; Animals; Caprylates; Cell Culture Techniques; Cell Line, Tumor; Culture | 2012 |
Simultaneous measurement of gastric emptying with a simple muffin meal using [13C]octanoate breath test and scintigraphy in normal subjects and patients with dyspeptic symptoms.
Topics: Adolescent; Adult; Breath Tests; Caprylates; Carbon Isotopes; Dyspepsia; Female; Gastric Emptying; H | 2002 |
Validation of the 13C-octanoic acid breath test for measurement of equine gastric emptying rate of solids using radioscintigraphy.
Topics: Animals; Breath Tests; Caprylates; Carbon Dioxide; Carbon Isotopes; Female; Gastric Emptying; Horse | 2003 |
Oxidative breakdown of octanoic acid is maintained in patients with cirrhosis despite advanced disease.
Topics: Adult; Breath Tests; Caprylates; Carbon Isotopes; Female; Gastric Emptying; Humans; Liver Cirrhosis; | 2003 |
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test.
Topics: Breath Tests; Caprylates; Case-Control Studies; Fatty Liver; Female; Humans; Male; Mitochondria; Oxi | 2003 |
Short- and medium-term reproducibility of gastric emptying of a solid meal determined by a low dose of 13C-octanoic acid and nondispersive isotope-selective infrared spectrometry.
Topics: Adult; Breath Tests; Caprylates; Carbon Dioxide; Carbon Isotopes; Data Interpretation, Statistical; | 2006 |
Comparison between therapeutic antitoxin F(ab)2 fractionated with ammonium sulfate and caprylic acid.
Topics: Ammonium Sulfate; Antigen-Antibody Reactions; Antitoxins; Caprylates; Electrophoresis, Polyacrylamid | 2006 |
Population screening for medium-chain acyl-CoA dehydrogenase deficiency: analysis of medium-chain fatty acids and acylglycines in blood spots.
Topics: Acyl-CoA Dehydrogenase; Acyl-CoA Dehydrogenases; Caprylates; Child, Preschool; Decanoic Acids; Fatty | 1994 |
Suppression of the inhibitory effect of denatured albumin on the polymerase chain reaction by sodium octanoate: application to routine clinical detection of hepatitis B virus at its infectivity threshold in serum.
Topics: Blood Proteins; Caprylates; DNA-Directed DNA Polymerase; DNA, Viral; Hepatitis B; Hepatitis B virus; | 1993 |
13C-octanoic acid breath test for gastric emptying measurement.
Topics: Adolescent; Adult; Aged; Breath Tests; Caprylates; Carbon Isotopes; Case-Control Studies; Female; Ga | 2000 |